跳至主要内容
临床试验/CTRI/2020/06/025922
CTRI/2020/06/025922已完成未知

Efficacy of Vamana, Virechana and Basti followed by Shamana in the Management of Sthula Pramehi w.s.r. to Type 2 Diabetes - An Open Labelled Randomized Standard Controlled Clinical Trial

IPGT AND RA GAU Jamnagar0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Patient having classical signs and symptoms of the disease.
  • 2)Patients of having BMI >25 ââ?¬â?? 35 kg/m2
  • 3)Patient of Type 2 Diabetes with blood sugar level, FBS - 126 to 300 mg/dl or
  • PPBS - 200 to 350 mg/dl or HbA1C% - ââ?°Â¥6.5% To 12%
  • 4)Age group of 20-60 years.
  • 5)Patient fit for Vamana and Virechana and Basti Karma.

排除标准

  • 1)Age < 20 yrs. and > 60 yrs.
  • 2)Patients of Type-2 Diabetes having BMI < 25 & >35 kg/m2 and Disease Chronicity > 10yrs.
  • 3)Patients of Type-1 Diabetes or the patients of Type-2 Diabetes taking Insulin.
  • 4)Patients having complications of Diabetes like Nephropathy, Retinopathy, Diabetic Foot, Carbuncles etc.
  • 5)PatientshavingDiabetesinassociationwithotherendocrinopathieslike Pheochromocytoma, Acromegaly, Cushingââ?¬•s syndrome, hyperthyroidism etc.
  • 6)Patients having drug or chemical induced Type 2 Diabetes, like glucocorticoids induced or thyroid hormone induced etc.
  • 7)Patients with genetic syndromes associated with Type 2 Diabetes like Downââ?¬•s Syndrome, Klinefelterââ?¬•s Syndrome, Turnerââ?¬•s syndrome etc.
  • 8)Patients complicated with any cardiovascular diseases, renal diseases, Carcinoma or any other disease effecting multiple body systems and pregnant women etc.
  • 9)Patient not fit for Vamana and Virechana and Basti Karma.

研究者

发起方
IPGT AND RA GAU Jamnagar

相似试验